BioSpace News Archive

Moderna, Inc. today announced that John Mendlein, Ph.D., President of Corporate and Product Strategy, will be leaving the Company effective February 1, 2019 to join Flagship Pioneering as an Executive Partner. He will be a strategic consultant to Moderna for six months to ensure a smooth transition.

Proven Pharmaceutical Leader Brings Deep, Global Experience with Successful Product Launches, Commercialization and Strategic Planning

Can-Fite BioPharma Ltd. today announced that it has entered into a definitive agreement with a single institutional investor to receive gross proceeds of approximately $2.35 million.

Fourdesire, an innovative mobile design studio, today announced the launch of the second version of their popular mobile app, Plant Nanny.

The Georgia Mesothelioma Victims Center says, “If you are a US Navy Veteran who has recently been diagnosed with mesothelioma or asbestos exposure lung cancer and you live in Georgia or you are their family member please call us anytime at 800-714-0303 so at a minimum you can receive incredibly honest advice about what specific mesothelioma attorneys you should be talking to.

AOTI Inc. announced today that it has entered into a major strategic relationship with a leading Chinese medical company, Nanning Xinzizhu Trading Co.,Ltd, for distribution of its patented Topical Wound Oxygen (TWO2) therapy wound healing products into the People’s Republic of China

Stepscan Technologies Inc. announced today the launch of its new mobility assessment tool specifically to address the growing problem of accidental falls in hospitals and Long-Term Care facilities.

Great Place to Work and FORTUNE named Medidata (NASDAQ:MDSO) one of the 2019 Best Workplaces in Technology. The company was selected 25th among large companies.

Nevada Donor Network (NDN) is proud to announce its sixth record-breaking year out of the last seven in the number of lives saved and healed through organ, eye and tissue donation.

Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $2.2 million of its common stock in a registered direct offering.